title: [Pharmacokinetics/pharmacodinamic (PK/PD) evaluation of a short course of oral administration of metronidazole for the management of infections caused by Bacteroides fragilis].
abstract: BACKGROUND
  Metronidazole is the antibiotic of choice for the management of infections caused by anaerobes. Its administration requires multiple daily doses causing increased medication errors. Due to its high post-antibiotic effect and rapid concentration-dependent bactericidal activity, administration of this antibiotic in an extended dosing interval would achieve PK/PD parameters effectively.
  
  
  OBJECTIVE
  To assess the probability of achieving effective PK/PD relationship with the administration of 1,000 mg every 24 hours of metronidazole for Bacteroides fragilis infections.
  
  
  METHODS
  A clinical trial was conducted in a group of volunteers who received a single oral dose of 500 or 1,000 mg of metronidazole. Determinations of values of Cmax, t max, and AUCC0-24 h. determined using the trapezoidal method, were obtained for a Markov simulation that would allow for determining the likelihood of achieving a AUC0-24 h/MIC ratio above 70 for infections caused by susceptible B. fragilis.
  
  
  RESULTS
  Cmax (24,03 ± 6,89 mg/L) and t max (1,20 ± 0.80 hrs) and the value of AUC0-24 h (241.91 ± 48.14 mg * h/L) were determined. The probability of obtaining a AUC0-24 h/MIC ratio greater than 70 was greater than 99%.
  
  
  CONCLUSIONS
  From a pharmacokinetic perspective, with the administration of a daily dose of 1,000 mg of metronidazole, it is possible to achieve a therapeutic goal of AUC0-24 h/MIC ratio above 70 for the treatment of anaerobic infections.
authors.forename: Felipe
authors.initials: F
authors.lastname: Morales-León
authors.forename: Carlos
authors.initials: C
authors.lastname: von Plessing-Rossel
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Villa-Zapata
authors.forename: Pola
authors.initials: P
authors.lastname: Fernández-Rocca
authors.forename: Cindy
authors.initials: C
authors.lastname: Sanhueza-Sanhueza
authors.forename: Helia
authors.initials: H
authors.lastname: Bello-Toledo
authors.forename: Sergio
authors.initials: S
authors.lastname: Mella-Montecinos
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001442:Bacteroides Infections / Q000188:drug therapy* / Q000378:metabolism*; D001441:Bacteroides fragilis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D008795:Metronidazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D008795:Metronidazole